 |
World's first triple hormone ovarian reserve test. Biofusion plc ("Biofusion") today announces its portfolio company, Lifestyle Choices Ltd ("Lifestyle Choices"), has launched its new triple hormone ovarian reserve test, Plan Ahead. Lifestyle Choices believes this test offers the most accurate hormone based ovarian reserve test available to the public, enabling women to make more informed decisions about whether to try for a baby sooner rather than later.
Developed by Professor Bill Ledger, Professor of Obstetrics and Gynaecology at the University of Sheffield, Plan Ahead measures three hormone levels in the blood. The first two are the ovarian hormones, Inhibin B and AMH; and the third is FSH, a pituitary hormone. The result is a predictive assessment of the number of eggs in the woman's ovaries compared to levels expected for women of the same age. The test is accurate for up to two years ahead.
The test will initially be available by mail order and costs £179. It is anticipated that Plan Ahead will be available via pharmacies and private clinics later in the year.
Lifestyle Choices, which plans to offer a range of products in the female fertility and menopause markets, was founded by Biofusion in October 2005. Biofusion owns 50% of the company and provided initial seed financing of £65k, in the form of a repayable loan, to support the launch of the Plan Ahead.
David Baynes, CEO of Biofusion, said: "Female fertility and the choices women make about when to start a family attract a great deal of public interest and, through the work of Professor Ledger, one of the UK's leading fertility experts, Lifestyle Choices is well positioned to develop products and services to address this important market. Lifestyle Choices' launch of Plan Ahead also highlights a number of Biofusion's key strengths: its ability to bring a product or service quickly to market and the quality of science at the University of Sheffield. In addition, our portfolio has what we believe is an excellent mix of revenue generating companies and medium to longer term investment propositions "
|
